Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized pegylated interferon plus ribavirin retreatment in non-responsive chronic hepatitis C
ChiCTR-RNRC-10001089Phase 4Completed
- Sponsor
- Third Hospital of Hebei Medical University
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection (2 arms), sponsored by Third Hospital of Hebei Medical University. Primary endpoints: Sustained Virological Response, Individualized treatment regimen and 1 more. Started Jan 2010; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ChiCTR-RNRC-10001089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-RNRC-10001089.